Ananda Immunotherapies

Ananda Immunotherapies is a Singapore-based clinical-stage biotech developing next-generation immunotherapies to reverse autoimmunity by restoring immune tolerance through regulatory T cell induction. Their lead candidate, AI‑005, an oral peptide-drug conjugate for rheumatoid arthritis, has shown strong safety and efficacy data in earlier trials and will enter Phase II trials in Europe. The company’s broader pipeline includes both pharmacological and cell therapy approaches aimed at multiple autoimmune diseases, leveraging high-dimensional data and artificial intelligence to map the “immunome” and design network-wide interventions rather than traditional immunosuppression.